Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DPH3 | ISIN: US6876041087 | Ticker-Symbol: HQ1
Tradegate
22.04.25
16:28 Uhr
8,450 Euro
-0,900
-9,63 %
1-Jahres-Chart
ORUKA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ORUKA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,7008,85018:44
8,7008,85018:44

Aktuelle News zur ORUKA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ORUKA THERAPEUTICS Aktie jetzt für 0€ handeln
09.03.Oruka Therapeutics zeigt Fortschritte trotz Verlusten4
07.03.Stifel maintains Buy rating on Oruka Therapeutics stock, $49 target1
07.03.Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting1.747Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab...
► Artikel lesen
06.03.Oruka Therapeutics, Inc. Q4 Loss Narrows1
06.03.ARCA biopharma GAAP EPS of -$0.49 misses by $0.082
06.03.Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update112ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides...
► Artikel lesen
06.03.Oruka Therapeutics, Inc. - 10-K, Annual Report-
05.02.Oruka Therapeutics, Inc. - 8-K, Current Report1
19.12.24Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody202Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy...
► Artikel lesen
19.12.24Oruka Therapeutics, Inc. - 8-K, Current Report-
18.12.24Oruka Therapeutics, Inc.: Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)162MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment...
► Artikel lesen
14.11.24Oruka Therapeutics, Inc. - 8-K, Current Report-
14.11.24Oruka Therapeutics files to sell 8.72M shares of common stock for holders3
14.11.24Oruka Therapeutics, Inc. - S-1, General form for registration of securities-
14.11.24Oruka Therapeutics GAAP EPS of -$1.46 misses by $1.083
13.11.24Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update161Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro...
► Artikel lesen
13.11.24Oruka Therapeutics, Inc. - 10-Q, Quarterly Report-
27.09.24XFRA HQ1: WIEDERAUFNAHME/RESUMPTION296FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
25.09.24Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress236Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent potency to risankizumab with similar binding...
► Artikel lesen
03.09.24XFRA HQ1: AUSSETZUNG/SUSPENSION412DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILORUKA THERAPEUTICS...
► Artikel lesen
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1